Effect of 5-lipoxygenase on the development of pulmonary hypertension in rats

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 286, Issue 5 55-5, 2004, Pages

  Jones, John E ^a   Walker, Jennifer L ^a   Song, Yanli ^a   Weiss, Norbert ^a   Cardoso, Wellington V ^a   Tuder, Rubin M ^b   Loscalzo, Joseph ^a   Zhang, Ying Yi ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Inflammation; Monocrotaline

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ARACHIDONATE 5 LIPOXYGENASE; GREEN FLUORESCENT PROTEIN; LIPOXYGENASE INHIBITOR; MONOCROTALINE; VIRUS VECTOR; ZILEUTON;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DISEASE COURSE; GENE OVEREXPRESSION; HEART CATHETERIZATION; HEART LEFT VENTRICLE; HEART RIGHT VENTRICLE; HEART VENTRICLE SEPTUM; HISTOLOGY; INFLAMMATORY CELL; LUNG; LUNG ARTERY PRESSURE; LUNG PARENCHYMA; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT; TRANSTHORACIC ECHOCARDIOGRAPHY; VIRUS RECOMBINANT;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; DRUG SYNERGISM; GENE TRANSFER TECHNIQUES; HEART SEPTUM; HEART VENTRICLES; HYPERTENSION, PULMONARY; LUNG; MALE; MONOCROTALINE; MYOCARDIUM; ORGAN SIZE; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 1942501625     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00281.2003     Document Type: Article

References (43)

1. Ahmed T and Oliver W Jr. Does slow-reacting substance of anaphylaxis mediate hypoxic pulmonary vasoconstriction? Am Rev Respir Dis 127: 566-571, 1983.
2. Allen JR and Carstens LA. Pulmonary vascular occlusions initiated by endothelial lysis in monocrotaline-intoxicated rats. Exp Mol Pathol 13: 159-171, 1970.
3. Avis IM, Jett M, Boyle T, Vos MD, Moody T, Treston AM, Martinez A, and Mulshine JL. Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Invest 97: 806-813, 1996.
4. Back M, Norel X, Walch L, Gascard J, de Montpreville V, Dahlen S, and Brink C. Prostacyclin modulation of contractions of the human pulmonary artery by cysteinyl-leukotrienes. Eur J Pharmacol 401: 389-395, 2000.
5. Berkowitz BA, Zabko-Potapovich B, Valocik R, and Gleason JG. Effects of the leukotrienes on the vasculature and blood pressure of different species. J Pharmacol Exp Ther 229: 105-112, 1984.
6. Borgeat P and Samuelsson B. Arachidonic acid metabolism in polymorphonuclear leukocytes: unstable intermediate in formation of dihydroxy acids. Proc Natl Acad Sci USA 76: 3213-3217, 1979.
7. Bruner LH, Hilliker KS, and Roth RA. Pulmonary hypertension and ECG changes from monocrotaline pyrrole in the rat. Am J Physiol Heart Circ Physiol 245: H300-H306, 1983.
8. Butler WH, Mattocks AR, and Barnes JM. Lesions in the liver and lungs of rats given pyrrole derivatives of pyrrolizidine alkaloids. J Pathol 100: 169-175, 1970.
9. Dahlen SE, Bjork J, Hedqvist P, Arfors KE, Hammarstrom S, Lindgren JA, and Samuelsson B. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci USA 78: 3887-3891, 1981.
10. Dahlen SE, Hedqvist P, Hammarstrom S, and Samuelsson B. Leukotrienes are potent constrictors of human bronchi. Nature 288: 484-486, 1980.
11. 2 in eicosanoid generation. Am J Respir Crit Care Med 161: S32-S35, 2000.
12. Dixon RA, Diehl RE, Opas E, Rands E, Vickers PJ, Evans JF, Gillard JW, and Miller DK. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 343: 282-284, 1990.
13. Drazen JM, Austen KF, Lewis RA, Clark DA, Goto G, Marfat A, and Corey EJ. Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc Natl Acad Sci USA 77: 4354-4358, 1980.
14. Ford-Hutchinson AW, Bray MA, Doig MV, Shipley ME, and Smith MJ. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 286: 264-265, 1980.
15. Ghodsi F and Will JA. Changes in pulmonary structure and function induced by monocrotaline intoxication. Am J Physiol Heart Circ Physiol 240: H149-H155, 1981.
16. Goldberg RN, Suguihara C, Ahmed T, de Cudemus BD, Barrios P, Setzer ES, and Bancalari E. Influence of an antagonist of slow-reacting substance of anaphylaxis on the cardiovascular manifestations of hypoxia in piglets. Pediatr Res 19: 1201-1205, 1985.
17. Hanna CJ, Bach MK, Pare PD, and Schellenberg RR. Slow-reacting substances (leukotrienes) contract human airway and pulmonary vascular smooth muscle in vitro. Nature 290: 343-344, 1981.
18. Jones JE, Mendes L, Rudd MA, Russo G, Loscalzo J, and Zhang YY. Serial noninvasive assessment of progressive pulmonary hypertension in a rat model. Am J Physiol Heart Circ Physiol 283: H364-H371, 2002.
19. Kimura H, Kasahara Y, Kurosu K, Sugito K, Takiguchi Y, Terai M, Mikata A, Natsume M, Mukaida N, Matsushima K, and Kuriyama T. Alleviation of monocrotaline-induced pulmonary hypertension by antibodies to monocyte chemotactic and activating factor/monocyte chemoattractant protein-1. Lab Invest 78: 571-581, 1998.
20. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA, 3rd Loyd JE, Nichols WC, and Trembath RC. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium Nat Genet 26: 81-84, 2000.
21. Lepley RA and Fitzpatrick FA. 5-Lipoxygenase contains a functional Src homology 3-binding motif that interacts with the Src homology 3 domain of Grb2 and cytoskeletal proteins. J Biol Chem 269: 24163-24168, 1994.
22. Meyrick B and Reid L. Development of pulmonary arterial changes in rats fed Crotalaria spectabilis. Am J Pathol 94: 37-51, 1979.
23. Morganroth ML, Reeves JT, Murphy RC, and Voelkel NF. Leukotriene synthesis and receptor blockers block hypoxic pulmonary vasoconstriction. J Appl Physiol 56: 1340-1346, 1984.
24. Morganroth ML, Stenmark KR, Morris KG, Murphy RC, Mathias M, Reeves JT, and Voelkel NF. Diethylcarbamazine inhibits acute and chronic hypoxic pulmonary hypertension in awake rats. Am Rev Respir Dis 131: 488-492, 1985.
25. Morganroth ML, Stenmark KR, Zirrolli JA, Mauldin R, Mathias M, Reeves JT, Murphy RC, and Voelkel NF. Leukotriene C4 production during hypoxic pulmonary vasoconstriction in isolated rat lungs. Prostaglandins 28: 867-875, 1984.
26. Murphy RC, Hammarstrom S, and Samuelsson B. Leukotriene C: a slow-reacting substance from murine mastocytoma cells. Proc Natl Acad Sci USA 76: 4275-4279, 1979.
27. Peppelenbosch MP, Tertoolen LG, Hage WJ, and de Laat SW. Epidermal growth factor-induced actin remodeling is regulated by 5-lipoxygenase and cyclooxygenase products. Cell 74: 565-575, 1993.
28. Piperno D, Pacheco Y, Hosni R, Moliere P, Gharib C, Lagarde M, and Perrin-Fayolle M. Increased plasma levels of atrial natriuretic factor, renin activity, and leukotriene C4 in chronic obstructive pulmonary disease. Chest 104: 454-459, 1993.
29. Provost P, Doucet J, Hammarberg T, Gerisch G, Samuelsson B, and Radmark O. 5-Lipoxygenase interacts with coactosin-like protein. J Biol Chem 276: 16520-16527, 2001.
30. Provost P, Samuelsson B, and Radmark O. Interaction of 5-lipoxygenase with cellular proteins. Proc Natl Acad Sci USA 96: 1881-1885, 1999.
31. Schreiber MD, Heymann MA, and Soifer SJ. Leukotriene inhibition prevents and reverses hypoxic pulmonary vasoconstriction in newborn lambs. Pediatr Res 19: 437-441, 1985.
32. Shimizu T, Radmark O, and Samuelsson B. Enzyme with dual lipoxygenase activities catalyzes leukotriene A4 synthesis from arachidonic acid. Proc Natl Acad Sci USA 81: 689-693, 1984.
33. Stenmark KR, James SL, Voelkel NF, Toews WH, Reeves JT, and Murphy RC. Leukotriene C4 and D4 in neonates with hypoxemia and pulmonary hypertension. N Engl J Med 309: 77-80, 1983.
34. Stenmark KR, Morganroth ML, Remigio LK, Voelkel NF, Murphy RC, Henson PM, Mathias MM, and Reeves JT. Alveolar inflammation and arachidonate metabolism in monocrotaline-induced pulmonary hypertension. Am J Physiol Heart Circ Physiol 248: H859-H866, 1985.
35. Thomson JR, Machado RD, Pauciulo MW, Morgan NV, Humbert M, Elliott GC, Ward K, Yacoub M, Mikhail G, Rogers P, Newman J, Wheeler L, Higenbottam T, Gibbs JS, Egan J, Crozier A, Peacock A, Allcock R, Corris P, Loyd JE, Trembath RC, and Nichols WC. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-11, a receptor member of the TGF-beta family. J Med Genet 37: 741-745, 2000.
36. Trembath RC, Thomson JR, Machado RD, Morgan NV, Atkinson C, Winship I, Simonneau G, Galie N, Loyd JE, Humbert M, Nichols WC, Morrell NW, Berg J, Manes A, McGaughran J, Pauciulo M, and Wheeler L. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 345: 325-334, 2001.
37. Voelkel NF, Tuder RM, Bridges J, and Arend WP. Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline. Am J Respir Cell Mol Biol 11: 664-675, 1994.
38. Voelkel NF, Tuder RM, Wade K, Hoper M, Lepley RA, Goulet JL, Koller BH, and Fitzpatrick F. Inhibition of 5-lipoxygenase-activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats. J Clin Invest 97: 2491-2498, 1996.
39. Walker JL, Loscalzo J, and Zhang YY. 5-Lipoxygenase and human pulmonary artery endothelial cell proliferation. Am J Physiol Heart Circ Physiol 282: H585-H593, 2002.
40. Wilson DW, Segall HJ, Pan LC, and Dunston SK. Progressive inflammatory and structural changes in the pulmonary vasculature of monocrotaline-treated rats. Microvasc Res 38: 57-80, 1989.
41. Wright L, Tuder RM, Wang J, Cool CD, Lepley RA, and Voelkel NF. 5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. Am J Respir Crit Care Med 157: 219-229, 1998.
42. Yeager ME, Halley GR, Golpon HA, Voelkel NF, and Tuder RM. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ Res 88: E2-E11, 2001.
43. Zhang YY, Walker JL, Huang A, Keaney JF, Clish CB, Serhan CN, and Loscalzo J. Expression of 5-lipoxygenase in pulmonary artery endothelial cells. Biochem J 361: 267-276, 2002.